Indoloquinoline Compounds Inhibiting Telomerase and DNA Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compounds for treating various cancers lack efficacy and are difficult to prepare, necessitating the development of new indolo[3,2-c]quinoline compounds with enhanced anticancer properties.
Innovation Solution
Development of novel indolo[3,2-c]quinoline compounds of specific formulas, which can inhibit DNA replication or transcription in tumor cells, thereby exhibiting potent anticancer activity by contacting or administering them to subjects in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmaceutical compounds are used for treating cancers, then treatment options are available, but they lack efficacy and are difficult to prepare
Solution Approach 1:
The patent modifies the chemical structure of indolo[3,2-c]quinoline compounds by varying substituents at different positions (R1-R6 groups) to optimize both anticancer efficacy and manufacturability. Specific parameter changes include introducing hydroxyl, alkoxy, alkyl, and heterocyclic groups at strategic positions to enhance biological activity while maintaining synthetic accessibility
Solution Approach 2:
The patent creates composite molecular structures by combining the indolo[3,2-c]quinoline core with various functional groups and heterocyclic systems. This composite approach allows the molecules to exhibit enhanced anticancer properties through multiple mechanisms (DNA intercalation, topoisomerase inhibition, telomerase suppression) while providing flexibility in synthesis routes
2Reliability
If indolo[3,2-c]quinoline compounds are designed to inhibit DNA replication, then anticancer activity is enhanced, but molecular complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct functional segments: the indolo[3,2-c]quinoline core responsible for DNA intercalation, and various substituent groups (R1-R6) that provide additional biological activities. This segmentation allows each part to contribute specifically to DNA replication inhibition while keeping the overall design modular and manageable
Solution Approach 2:
The patent designs compounds where the indolo[3,2-c]quinoline core serves multiple functions: it can intercalate into DNA, inhibit topoisomerase activity, and suppress telomerase function. This multi-functionality achieves enhanced anticancer activity through a single molecular scaffold, reducing the need for multiple separate complex molecules
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate significant activity against a range of cancer types, including leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer, with the ability to inhibit telomerase, suggesting a potential therapeutic effect.
Implementation Method 1
Indolo[3,2-c]quinoline compounds have a tetracyclic heterocycle that can intercalate into the double helix of DNA to block DNA replication or transcription
Data Source
AI summary
Disclosed herein are indolo[3,2-c]quinoline compounds of formula (I):or a pharmaceutically acceptable salt thereof,wherein R and m are given the definitions as set forth in the Specification and Claims.These compounds can be used to inhibit both growth of cancer cells and activity of telomerase.